Pharmaceutical and biologics firm AstraZeneca PLC announced its positive outcomes for its Faslodex drug from the Phase III hormonal therapy trial for treating breast cancer.
The company reported that the trial evaluated Faslodex 500 milligrams with Arimidex milligram for the treatment of metastatic breast cancer in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive breast cancer.
And the result: Faslodex was superior to Arimidez, and achieved its key endpoint of extended progression-free survival.
Aromatase inhibitors like Arimidex are the existing benchmark of care in first-line treatment for post-menopausal women with metastatic breast cancer.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca stated that, "The FALCON results bring us closer to offering more and earlier treatment options to post-menopausal women with HR+ locally-advanced or metastatic breast cancer; the potential to delay disease progression is important for these patients as there is currently no cure.”
He also added that Faslodex has more than a decade of clinical evidence and that they are dedicated to discovering more of its potential, along with the rest of their exceptional oncology portfolio.
AstraZeneca also revealed on Friday that the U.S. Food and Drug Administration has issued a Complete Response Letter in regards with New Drug Application for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed as a cure for hyperkalaemia, a high potassium level in the blood serum. It is wholly owned ZS Pharma, a subordinate of AstraZeneca. The CRL refers to observations arising from a pre-approval manufacturing inspection.
The company said that AstraZeneca and ZS Pharma are assessing the CRL’s content and will work closely with the FDA to decide the appropriate next steps for the New Drug Application.
1. Looking for the latest market updates? FSM News provides correct financial resources and news online. Subscribe now and receive newsletter daily.